Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1043Lung Neoplasms 800Small Cell Lung Carcinoma 193Breast Neoplasms 158Colorectal Neoplasms 156Neoplasms 128Melanoma 116Ovarian Neoplasms 111Pancreatic Neoplasms 106Stomach Neoplasms 95Neoplasm Metastasis 88Esophageal Neoplasms 77Squamous Cell Carcinoma of Head and Neck 75Prostatic Neoplasms 66Uterine Cervical Neoplasms 65Head and Neck Neoplasms 65Endometrial Neoplasms 61Triple Negative Breast Neoplasms 59Carcinoma, Renal Cell 58Colonic Neoplasms 57Mesothelioma, Malignant 48Adenocarcinoma of Lung 48Urinary Bladder Neoplasms 47Carcinoma, Hepatocellular 46Mesothelioma 42Sarcoma 40Brain Neoplasms 40Liver Neoplasms 38Disease 34NSCLC 33

Interventions

endostar protein 1Surgical Procedures, Operative 1Endostatins 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Unresectable Non-small Cell Lung Cancer × Thoracic × Clear all
NCT06617936 2025-07-15

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Shandong Public Health Clinical Center

Phase 2 Recruiting
36 enrolled
Thoracic

Unresectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡